Hypersensitivity Reactions to Transarterial Chemoembolization with Cisplatin and Ethiodized Oil: A Retrospective Cohort Study |
| |
| Affiliation: | 1. Department of Pharmacy, Tuen Mun Hospital, Hong Kong Special Administrative Region of the People’s Republic of China;2. Department of Radiology & Nuclear Medicine, Tuen Mun Hospital, Hong Kong Special Administrative Region of the People’s Republic of China;1. Division of Vascular and Interventional Radiology, Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin;2. Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin;3. Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania;4. Division of Vascular and Interventional Radiology, Department of Radiology, University of California San Diego, La Jolla, California;1. St George’s University School of Medicine, Grenada, West Indies;2. Prostate Centers USA, Falls Church, VA;1. Division of Interventional Radiology, Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins Hospital, Baltimore, Maryland;2. Center for Health Services and Outcomes Research, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland;3. Johns Hopkins University School of Medicine, Baltimore, Maryland;4. Department of Dermatology, Johns Hopkins Hospital, Baltimore, Maryland |
| |
| Abstract: | PurposeTo assess the incidence of hypersensitivity reactions (HSRs) and risk factors in patients with unresectable hepatocellular carcinoma (HCC) who have undergone transarterial chemoemblization (TACE) with cisplatin–ethiodized oil emulsion.Materials and MethodsBetween September 2014 and December 2019, patients with HCC in the authors’ institution undergoing TACE with cisplatin–ethiodized oil emulsion were retrospectively reviewed. Clinical, laboratory, and imaging data (including age, sex, etiology of HCC, serum bilirubin, albumin, alpha-fetoprotein, prothrombin time, dose of cisplatin, and details of TACE procedure) and data on procedural complications were retrieved from the registry of TACE. The incidence of HSRs was calculated, and variables were compared between the patient groups with and without HSRs. Predictive factors were analyzed using binary logistic regression.ResultsA total of 882 TACE procedures were involved in 257 patients with HCC. The median number of TACE procedures performed per patient was 3 (range, 1–23). The median dose of cisplatin per TACE session was 4.58 mg (range, 0.42–21 mg), and the median accumulated dose of cisplatin per patient was 15.42 mg (range, 0.52–125 mg). HSRs were identified in 22 (2.49%) of 882 procedures (17 [6.61%] of 257 patients). The median number of TACE procedures performed in these patients was 2.5 (range, 1–17). The median dose of cisplatin per TACE session was 5.42 mg (range, 0.63–20 mg), and the median accumulated dose of cisplatin per patient was 18.44 mg (range, 3.33–47.99 mg). Upon binary logistic regression analysis, parameters that showed statistically significant and independent association with HSRs included performance of ≥6 TACE procedures (odds ratio, 3.773; P = .012).ConclusionsPerformance of ≥6 TACE procedures was found to be independently associated with the incidence of HSRs. Patients undergoing multiple TACE procedures should be monitored closely for HSRs. |
| |
| Keywords: | CT" },{" #name" :" keyword" ," $" :{" id" :" kwrd0015" }," $$" :[{" #name" :" text" ," _" :" computed tomography HCC" },{" #name" :" keyword" ," $" :{" id" :" kwrd0025" }," $$" :[{" #name" :" text" ," _" :" hepatocellular carcinoma HSR" },{" #name" :" keyword" ," $" :{" id" :" kwrd0035" }," $$" :[{" #name" :" text" ," _" :" hypersensitivity reaction TACE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0045" }," $$" :[{" #name" :" text" ," _" :" transarterial chemoembolization |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
